RayKnowChina Research Map
Shortlist

Tianjin

Tianjin First Central Hospital

天津市第一中心医院

Listed for 18 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Tianjin First Central Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌45 papers led
  2. Lung cancer肺癌19 papers led1 open trial led
  3. Hepatoblastoma肝母细胞瘤1 paper led
  4. Chordoma脊索瘤1 paper led
  5. Osteosarcoma骨肉瘤3 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Neuroblastoma神经母细胞瘤0 papers led
  8. Multiple myeloma多发性骨髓瘤8 papers led
  9. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  10. Lymphoma淋巴瘤21 papers led
  11. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  12. Biliary atresia胆道闭锁9 papers led
  13. Coronary heart disease冠心病3 papers led
  14. Congenital heart disease先天性心脏病3 papers led
  15. Takayasu arteritis大动脉炎1 paper led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  18. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Retinoblastoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Scoliosis, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 45 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
45
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 9920212022: 7720222023: 101020232024: 6620242025: 12122025

4 hospitals in Tianjin for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led45
  1. Ultrasound-activated piezoelectric BZT Nanocubes mediate direct Piezocatalytic killing and reverse immunosuppressive tumor microenvironment for effective hepatocellular carcinoma therapy.2026International immunopharmacology
  2. NFAT2 promotes sorafenib resistance in hepatocellular carcinoma cells by modulating calcium ion signalling.2025Archives of biochemistry and biophysics
  3. VETC predicting model based on CE-CT can predict prognosis and assisting treatment plan for solitary HCC: better together with radiomics.2025BMC cancerFree full text
  4. CT-based deep learning radiomics model for predicting proliferative hepatocellular carcinoma: application in transarterial chemoembolization and radiofrequency ablation.2025BMC medical imagingFree full text
  5. Discovery of novel transforming growth factor β type 1 receptor inhibitors through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation in hepatocellular carcinoma.2025Bioorganic & medicinal chemistry
  6. Lung cancer associated transcript 1 binds heat shock protein 90 to promote growth of hepatocellular carcinoma.2025Cellular signalling
  7. Mechanisms of innate immune cells in Metabolic dysfunction-associated steatotic liver disease.2025Frontiers in immunologyFree full text
  8. Multi-omics identification of a polyamine metabolism related signature for hepatocellular carcinoma and revealing tumor microenvironment characteristics.2025Frontiers in immunologyFree full text
  9. IGF2BP3-STAT3-METTL3 axis promotes malignant progression in hepatocellular carcinoma (HCC).2025Human genomicsFree full text
  10. The predictive value of 18F-FDG PET/CT metabolic parameters and radiomics characteristics for microvascular invasion of hepatocellular carcinoma.2025Radiography (London, England : 1995)
  11. Gadoxetic Acid-enhanced MRI Scoring Model to Predict Pathologic Features of Hepatocellular Carcinoma.2025Radiology
  12. SEL1L-mediated endoplasmic reticulum associated degradation inhibition suppresses proliferation and migration in Huh7 hepatocellular carcinoma cells.2025World journal of gastroenterologyFree full text
  13. Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression.2025World journal of gastroenterologyFree full text
  14. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.2024AgingFree full text
  15. COPS8 promotes hepatocellular carcinoma progression through the PI3K/AKT/mTOR pathway.2024Asian journal of surgery
  16. Integrative analysis based on ATAC-seq and RNA-seq reveals a novel oncogene PRPF3 in hepatocellular carcinoma.2024Clinical epigeneticsFree full text
  17. Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma.2024Hepatology international
  18. Spatial transcriptomics reveals tumor-derived SPP1 induces fibroblast chemotaxis and activation in the hepatocellular carcinoma microenvironment.2024Journal of translational medicineFree full text
  19. Phosphorylation of RasGRP1 by Shc3 prevents RasGRP1 degradation and contributes to Ras/c-Jun activation in hepatocellular carcinoma.2024Molecular and cellular biochemistry
  20. Simultaneous resection of synchronous multiple primary cancers: A case report and literature review.2023Asian journal of surgery
  21. A novel predictive model of microvascular invasion in hepatocellular carcinoma based on differential protein expression.2023BMC gastroenterologyRCTFree full text
  22. Added value of CE-CT radiomics to predict high Ki-67 expression in hepatocellular carcinoma.2023BMC medical imagingFree full text
  23. HepaClear, a blood-based panel combining novel methylated CpG sites and protein markers, for the detection of early-stage hepatocellular carcinoma.2023Clinical epigeneticsFree full text
  24. Integrative Multi-Omics Analysis of Identified Ferroptosis-Marker RPL8 as a Candidate Oncogene Correlates with Poor Prognosis and Immune Infiltration in Liver Cancer.2023Combinatorial chemistry & high throughput screening
  25. The Different Prognoses of Hepatocellular Carcinoma with Previous Tenofovir versus Entecavir Treatment for Chronic Hepatitis B Virus: Analysis Based on 15 Propensity Score-Matched Studies.2023Digestive diseases (Basel, Switzerland)
  26. Radiomics nomogram for the prediction of microvascular invasion of HCC and patients' benefit from postoperative adjuvant TACE: a multi-center study.2023European radiology
  27. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  28. Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4+ T cells after liver transplantation in rat.2023International immunopharmacology
  29. Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway.2023Oxidative medicine and cellular longevityFree full text
  30. Preoperative determination of pathological grades of primary single HCC: development and validation of a scoring model.2022Abdominal radiology (New York)
  31. HBX suppresses PTEN to promote the malignant progression of hepatocellular carcinoma through mi-R155 activation.2022Annals of hepatology
  32. 23-hydroxybetulinic acid reduces tumorigenesis, metastasis and immunosuppression in a mouse model of hepatocellular carcinoma via disruption of the MAPK signaling pathway.2022Anti-cancer drugs
  33. Circular dorsal ruffles disturb the growth factor-induced PI3K-AKT pathway in hepatocellular carcinoma Hep3B cells.2022Cell communication and signaling : CCSFree full text
  34. Prediction of microvascular invasion in HCC by a scoring model combining Gd-EOB-DTPA MRI and biochemical indicators.2022European radiology
  35. Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing.2022Frontiers in immunologyFree full text
  36. Clinical characteristics and survival analysis of liver transplantation in patients with alcoholic liver disease: A single-center retrospective study.2022Transplant immunology
  37. Long non-coding RNA BACE1-AS plays an oncogenic role in hepatocellular carcinoma cells through miR-214-3p/APLN axis.2021Acta biochimica et biophysica Sinica
  38. DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma.2021AgingFree full text
  39. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.2021AgingFree full text
  40. Long non-coding RNAs HERH-1 and HERH-4 facilitate cyclin A2 expression and accelerate cell cycle progression in advanced hepatocellular carcinoma.2021BMC cancerFree full text
  41. Gene Expression Characteristics of Liver Tissue Reveal the Underlying Pathogenesis of Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  42. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.2021BioMed research internationalFree full text
  43. MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma.2021Cancer chemotherapy and pharmacology
  44. The Akt/GSK3β/β-catenin signaling regulated by ZCCHC14 is responsible for accelerating the proliferation of hepatocellular carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  45. Upregulated microRNA-132 in T helper 17 cells activates hepatic stellate cells to promote hepatocellular carcinoma cell migration in vitro.2021Scandinavian journal of immunology
All its trials on ClinicalTrials.gov, any status2
  1. Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular CarcinomaSuspendedNCT06405061Study sitePhase 2Start 2024-05
  2. A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial ChemoembolizationCompletedNCT06503250Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 19 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.08%.

Papers led
19
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 7720222023: 2220232024: 2220242025: 222025

7 hospitals in Tianjin for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    NK Cells Plus ICI for SCLC Maintenance
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07759856

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin First Central HospitalTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineMedical oncology

Over half of these papers are lab or animal studies.

Papers it led19
  1. Anoikis classification of lung squamous cell carcinoma reveals correlation with clinical prognosis and immune characteristics.2025Annals of medicineFree full text
  2. miR-224-5p Suppresses Non-Small Cell Lung Cancer via IL6ST-Mediated Regulation of the JAK2/STAT3 Pathway.2025Thoracic cancerFree full text
  3. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.2024Cancer medicineFree full text
  4. The Mediating Role of miR-451/ETV4/MMP13 Signaling Axis on Epithelialmesenchymal Transition in Promoting Non-small Cell Lung Cancer Progression.2024Current molecular pharmacology
  5. Prognostic value of pretreatment FDG PET-CT for short-term efficacy of radioactive iodine-125 seed implantation in patients with NSCLC.2023Brachytherapy
  6. Trousseau's syndrome in a non-small cell lung cancer patient aggravated by pembrolizumab.2023Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  7. 23-hydroxybetulinic acid reduces tumorigenesis, metastasis and immunosuppression in a mouse model of hepatocellular carcinoma via disruption of the MAPK signaling pathway.2022Anti-cancer drugs
  8. Cancer-released exosomal circular RNA circ_0008717 promotes cell tumorigenicity through microRNA-1287-5p/P21-activated kinase 2 (PAK2) axis in non-small cell lung cancer.2022BioengineeredFree full text
  9. RAB26 contributes to the progression of non-small cell lung cancer after being transcriptionally activated by SMAD3.2022BioengineeredFree full text
  10. The circ-PITX1 promotes non-small cell lung cancer development via the miR-30e-5p/ITGA6 axis.2022Cell cycle (Georgetown, Tex.)Free full text
  11. Small molecule TKI inhibitors affect the development of non-small cell carcinoma through HIPPO/YAP/PD-L1.2022Cellular and molecular biology (Noisy-le-Grand, France)
  12. Comprehensive Analysis of Centromere Protein Family Member Genes in Lung Adenocarcinoma.2022Critical reviews in eukaryotic gene expression
  13. Quercetin attenuates the proliferation of arsenic-related lung cancer cells via a caspase-dependent DNA damage signaling.2022Molecular carcinogenesis
  14. Clinical analysis of 125I seed implantation combined with Apatinib in the treatment of locally advanced lung cancer: A case series.2021JPMA. The Journal of the Pakistan Medical Association
  15. MiR-647 promotes cisplatin-induced cell apoptosis via downregulating IGF2 in non-small cell lung cancer.2021Minerva medica
  16. circCD151 promotes GLI2 expression by regulating miR‑30d‑5p and enhancing proliferation, invasion and stemness of lung cancer.2021Molecular medicine reportsFree full text
  17. A novel circular RNA, hsa_circ_0030998 suppresses lung cancer tumorigenesis and Taxol resistance by sponging miR-558.2021Molecular oncologyFree full text
  18. Establishment and validation of nomogram model for survival predicting in patients with spinal metastases secondary to lung cancer.2021Neurological research
  19. Identification of Key circRNAs in Non-Small Cell Lung Cancer.2021The American journal of the medical sciences
All its trials on ClinicalTrials.gov, any status1
  1. NK Cells Plus ICI for SCLC MaintenanceRecruitingNCT07759856Lead sponsorPhase 2Start 2026-08

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Tianjin for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Tianjin for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Metastatic sacral chordoma to the liver: A case report.2024Asian journal of surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

14 hospitals in Tianjin for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Tianjin for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Clinical analysis of liver transplantation in treatment of liver metastatic cancer].2016Zhonghua zhong liu za zhi [Chinese journal of oncology]

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Tianjin for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Clinical features and the molecular biomarkers of olfactory neuroblastoma.2018Pathology, research and practice

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 8 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.5%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 1120232024: 1120242025: 112025

5 hospitals in Tianjin for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesCAR-T & cell therapyRelapse & resistanceDiagnosis, MRD & risk
Departments in papersRadiology / nuclear medicine
Papers it led8
  1. Correlation between the expression of soluble BCMA and short-term/long-term curative effect and survival outcomes of anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma.2025Cell transplantationFree full text
  2. Diagnostic value of LGE and T1 mapping in multiple myeloma patients'heart.2024BMC cardiovascular disordersFree full text
  3. More accurate prediction of treatment response than mean apparent diffusion coefficient value in multiple myeloma using whole body MRI histogram analysis.2023Future oncology (London, England)
  4. Prediction of Early Treatment Response in Multiple Myeloma Using MY-RADS Total Burden Score, ADC, and Fat Fraction From Whole-Body MRI: Impact of Anemia on Predictive Performance.2022AJR. American journal of roentgenology
  5. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.2022Frontiers in immunologyFree full text
  6. Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.2022Hematological oncologyFree full text
  7. A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.2022Leukemia & lymphoma
  8. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.2021Frontiers in immunologyFree full text
Chinese-language papers (not in the count)1
  1. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

3 hospitals in Tianjin for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06481735

    Age 16 years to 70 years (registered criteria)

    Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyStem cell transplantPhiladelphia chromosome & genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 21 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 6620232024: 2220242025: 882025

4 hospitals in Tianjin for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  2. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology
Papers it led21
  1. Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.2025BMC cancerFree full text
  2. An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy.2025Cell transplantationFree full text
  3. Successful salvage therapy of ruxolitinib on interstitial pneumonia after long COVID or post-COVID-19 syndrome with follicular lymphoma: two case reports and literature review.2025Chinese clinical oncology
  4. A novel fourth generation of CAR-T cells: CD19 CAR-T cells engineered to express membrane-bound interleukin-15 and CXCR5 for the treatment of lymphoma.2025Clinical and experimental medicineFree full text
  5. Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma.2025Current cancer drug targets
  6. COVID-19 Infection Confirmed by Bronchoalveolar Lavage Fluid Metagenomics -Next-Generation Sequencing Instead of Pharyngeal Swabs in Follicular Lymphoma: Three-Case Report and Literature Review.2025Journal of clinical laboratory analysisFree full text
  7. Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma.2025Journal of translational medicineFree full text
  8. Post-Liver Transplantation-Burkitt Lymphoma in Children: A Single-Center Study of Clinical Characteristics, Treatment, and Outcomes.2025Pediatric transplantation
  9. Efficacy and side effects of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory gastrointestinal lymphoma.2024Cancer medicineFree full text
  10. Persistent Cytopenia After CD19 CAR T Therapy in Relapsed/Refractory DLBCL Patients Could Be a Predictor of Efficacy and Side Effects.2024Cell transplantationFree full text
  11. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.2023Annals of hematology
  12. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.2023Cell transplantationFree full text
  13. Epstein‒Barr virus-associated cellular immunotherapy.2023Cytotherapy
  14. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances.2023Frontiers in immunologyFree full text
  15. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lym2023Hematological oncology
  16. Mesenchymal stem cell suppresses the efficacy of CAR-T toward killing lymphoma cells by modulating the microenvironment through stanniocalcin-1.2023eLifeFree full text
  17. Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.2022Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  18. Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system.2022Leukemia & lymphoma
  19. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.2021Cancer immunology, immunotherapy : CIIFree full text
  20. Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect.2021Frontiers in immunologyFree full text
  21. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.2021Hematological oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Analysis of local reactions and efficacy of CD19 chimeric antigen receptor-modified T cells therapy in recurrent/refractory B-cell lymphoma with >7.5 cm lesions].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingNCT07896590Study sitePhase 3Start 2026-10
  2. Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06521255Study sitePhase 3Start 2024-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Tianjin for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [Advances in pathophysiology, diagnosis and treatment of adult severe-associated thrombotic microangiopathy].2023Zhonghua wei zhong bing ji jiu yi xue

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 9 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 4.2%.

Papers led
9
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 5520232024: 0020242025: 112025

2 hospitals in Tianjin for biliary atresia31 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesLiver transplantLong-term outcomesComplications after surgery
Departments in papersPediatricsRadiology / nuclear medicine
Papers it led9
  1. The pretransplant neutrophil-lymphocyte ratio is associated with postreperfusion syndrome and short-term outcomes after paediatric living-donor liver transplantation.2025Scandinavian journal of gastroenterology
  2. Impact of patent foramen ovale on short-term outcomes in children with biliary atresia undergoing living donor liver transplantation: a retrospective cohort study.2023BMC anesthesiologyFree full text
  3. Association between serum HMGB1 elevation and early pediatric acute respiratory distress syndrome: a retrospective study of pediatric living donor liver transplant recipients with biliary atresia in China.2023BMC anesthesiologyFree full text
  4. Risk factors for postreperfusion syndrome during living donor liver transplantation in paediatric patients with biliary atresia: a retrospective analysis.2023BMJ paediatrics openFree full text
  5. Impact of different ischemia times on biliary stricture after living donor liver transplantation with biliary atresia.2023Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  6. COL3A1, CXCL8, VCAN, THBS2, and COL1A2 are correlated with the onset of biliary atresia.2023MedicineFree full text
  7. Treatments and outcomes of intra-operative portal vein thrombosis in living-donor liver transplantation due to biliary atresia.2022Journal of pediatric surgery
  8. Impact of allograft types on outcomes after pediatric liver transplantation due to biliary atresia.2022Pediatric transplantation
  9. Pediatric living donor left lateral segment liver transplantation for biliary atresia: Doppler ultrasound findings in early postoperative period.2021Japanese journal of radiology
Chinese-language papers (not in the count)1
  1. [Risk factors of blood loss during liver transplantation in children with biliary atresia and its influence on prognosis].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status1
  1. Effect of Desflurane on Pediatric Acute Respiratory Distress Syndrome After Living Donor Liver Transplant RecipientsStatus unknownNCT05783518Lead sponsorPhase 4Start 2023-03
More papers found outside PubMed (not counted)2
  1. P.399: From ascites to rejection: Further recognizing antibody mediated rejection in pediatric living donor liver transplantation through case reports.2024Transplantationarticle
  2. WITHDRAWN: Identification and immunological characterization of cuproptosis-related molecular clusters in biliary atresia2023Journal of Pediatric Surgery Openretraction

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 3 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.06%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

9 hospitals in Tianjin for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CCTA Improves Clinical Management of Stable Chest Pain
    Phase
    Not given
    Started
    2016-01
    Posted
    Registry
    NCT04691037

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Chest Hospital; 2 listed hospitals as study sitesBeijing, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

6 hospitals in Tianjin for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Tianjin for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

10 hospitals in Tianjin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Tianjin for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

4 hospitals in Tianjin for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

天津市第一中心医院

Tianjin First Central Hospital

天津

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Tianjin First Center Hospital; Tianjin First Central Hospital Clinic Institute; Oriental Organ Transplant Center of Tianjin First Central Hospital; Tianjin First Centre Hospital; Tianjin First Central hospital; Biobank of Tianjin First Center Hospital; Biobank of Tianjin First Central Hospital; Tianjin No.1 Center Hospital

Suggest a correctionDownload the data